Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nasdaq  >  Evolus, Inc.    EOLS

EVOLUS, INC.

(EOLS)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsPress ReleasesOfficial PublicationsSector news

Evolus : Reports Third Quarter 2020 Results and Provides Business Update

10/30/2020 | 09:45am EST

NEWPORT BEACH - Evolus, Inc. (Nasdaq: EOLS), a performance beauty company with a customer-centric approach focused on delivering breakthrough products, today reported financial results for the third quarter ended September 30, 2020 and provided a business update.

'We reported third quarter net sales above expectations and are pleased with the strong underlying fundamentals of our business. We continued to leverage our highly efficient business model, including reducing our operating expenses by 38 percent as compared to the third quarter of last year,' said David Moatazedi, President and Chief Executive Officer. 'Despite the headwinds we have faced from the COVID-19 pandemic, our team has continued to execute on all fronts, resulting in the high growth of our Jeuveau business.'

Third Quarter 2020 Financial Results

$17.7 million in total net revenues for the third quarter of 2020 consisting of $16.9 million of U.S. Jeuveau net revenue and $0.7 million of net revenue from international sales. Third quarter net revenue increased 34% over the third quarter of 2019.

Gross margin percentage was 72.5%.

GAAP operating expenses decreased by 38% to $21.6 million from $34.6 million in the third quarter of 2019.

Non-GAAP operating expenses decreased by 34% to $19.3 million from $29.1 million in the third quarter of 2019. Non-GAAP operating expenses in the third quarter of 2020 exclude a gain resulting from the revaluation of the contingent royalty obligation of $2.5 million, stock-based compensation expense of $3.0 million and depreciation and amortization expense of $1.7 million. Non-GAAP operating expenses in the third quarter of 2019 exclude expenses resulting from the revaluation of the contingent royalty obligation of $1.8 million, stock-based compensation expense of $2.5 million and depreciation and amortization expense of $1.2 million.

GAAP loss from operations decreased by 65% to $8.8 million from $25.1 million in the third quarter of 2019.

Non-GAAP loss from operations decreased by 67% to $6.5 million from $19.6 million in the third quarter of 2019.

GAAP net loss decreased by 57% to $11.5 million from $27.0 million in the third quarter of 2019.

Cash, cash equivalents and short-term investments as of September 30, 2020 were $110.1 million, increased from $84.8 million as of June 30, 2020. In July 2020, the Company received a $40.0 million investment from its strategic partner, Daewoong Pharmaceutical Co. Ltd. in the form of a five-year, unsecured, subordinated, 3% convertible note at a conversion price of $13.00.

As of September 30, 2020, the Company had 33.7 million shares of common stock outstanding.

'We saw the Jeuveau launch trends accelerate as the market continued to rebound in the third quarter,' said Michael Jafar, Chief Marketing Officer. 'We achieved double digit growth in the number of new accounts added this quarter, reorder rates continue to rise and enrollment in our consumer loyalty program, Evolus Rewards, has exceeded our expectations.'

Key Business Highlights

Continued strong underlying market demand for Jeuveau in the third quarter of 2020 driven by a 14% increase in purchasing accounts compared to the second quarter of 2020 to over 5,000 accounts2. Reorder rates increased to 68% in the third quarter.

As of September 30, 2020, more than 2,200 purchasing accounts opted into the Evolus Rewards program and over 50,000 patients enrolled. Evolus Rewards is the Company's consumer loyalty program providing patients with improved affordability and instant savings.

Continued to leverage proprietary digital platform with more than 80% of orders in the third quarter originating from the Evolus Practice App.

On September 21, 2020, the United States International Trade Commission (USITC) confirmed their intent to review the July 6 non-binding initial determination of the Administrative Law Judge (ALJ). In July 2020, the ALJ issued an initial determination and recommended an exclusion order that, if confirmed by the USITC, would prevent the importation of Jeuveau into the United States for a period of ten years and a cease and desist order that would prevent the Company from selling Jeuveau in the United States for the same period of time. On October 22, 2020, the USITC issued a notice updating the target date for their final determination from November 6, 2020 to November 19, 2020.

Given the proximity to the final determination by the USITC on November 19, 2020, the Company has decided not to hold a third quarter 2020 earnings call.

About Evolus, Inc.

Evolus is a performance beauty company with a customer-centric approach focused on delivering breakthrough products. In 2019, the U.S. Food and Drug Administration approved Jeuveau (prabotulinumtoxinA-xvfs), the first and only neurotoxin dedicated exclusively to aesthetics and manufactured in a state-of-the-art facility using Hi-Pure technology. Jeuveau is powered by Evolus' unique technology platform and is designed to transform the aesthetic market by eliminating the friction points existing for customers today.

Forward-Looking Statements

This press release contains forward-looking statements as defined under the Private Securities Litigation Reform Act of 1995. All statements, other than statements of historical fact, are statements that could be deemed forward-looking statements, including statements that relate to the status of regulatory processes, future plans, events, prospects or performance and statements containing the words 'plans,' 'expects,' 'believes,' 'strategy,' 'opportunity,' 'anticipates,' 'outlook,' 'designed,' or other forms of these words or similar expressions, although not all forward-looking statements contain these identifying words. The Company's forward-looking statements include, but are not limited to, statements made by Mr. Moatazedi and Mr. Jafar related to the growth of Jeuveau sales, the rebound of the aesthetic market, the effectiveness of our customer and consumer programs, the efficiency of the Company's business model and expectations for future growth and our financial outlook as well as the Company's expectation that it has cash, cash equivalents and short term investments that will be sufficient to fund its operations for at least the next twelve months.

Forward-looking statements are based on current estimates and assumptions made by management of the Company and are believed to be reasonable, though they are inherently uncertain and difficult to predict.

Forward-looking statements involve risks and uncertainties that could cause actual results or experience to differ materially from that expressed or implied by the forward-looking statements. Other factors that could cause actual results or experience to differ materially from that expressed or implied by the forward-looking statements include uncertainties associated with our ability to generate revenue if the USITC affirms, in whole or in part, the initial determination issued by the ALJ in a final determination and imposes an exclusion order preventing us from importing Jeuveau into the United States and a cease and desist order that would prevent us from marketing and selling Jeuveau in the United States; the potential declaration of an event of default by certain of our lenders if the USITC affirms, in whole or in part, the initial determination by the ALJ; our future financial performance and our ability to continue as a going concern; the continued impact of COVID-19 on our business and the economy generally; the success of the launch of Jeuveau, customer and consumer adoption of Jeuveau, the efficiency and operability of our digital platform, competition and market dynamics, our ongoing legal proceedings and our ability to maintain regulatory approval of Jeuveau and other risks described in the section entitled 'Risk Factors' in our Quarterly Report on Form 10-Q for the quarter ended September 30, 2020 as filed with the Securities and Exchange Commission on October 29, 2020, which is available online at www.sec.gov. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof.

Use of Non-GAAP Financial Measures

Evolus' financial results are prepared in accordance with accounting principles generally accepted in the United States of America ('GAAP'). Management believes that non-GAAP operating expenses and non-GAAP loss from operations are useful in helping to identify the Company's core operating performance and enables management to consistently analyze the period-to-period financial performance of the core business operations. Management also believes that non-GAAP operating expenses and non-GAAP loss from operations will enable investors to assess the Company in the same way that management assesses the Company's current and future operations. The Company's definitions of non-GAAP operating expenses and non-GAAP loss from operations have limitations as an analytical tool and may differ from other companies reporting similarly named measures. Non-GAAP measures should be considered in addition to results prepared in accordance with GAAP but should not be considered a substitute for or superior to GAAP results.

Contact:

Ashwin Agarwal

Tel: +1-949-284-4559

Email: IR@Evolus.com

(C) 2020 Electronic News Publishing, source ENP Newswire

All news about EVOLUS, INC.
01/05EVOLUS, INC. : Termination of a Material Definitive Agreement, Results of Operat..
AQ
2020EVOLUS : Provides Update on United States International Trade Commission Case
AQ
2020US ITC Blocks Imports of Jeuveau Wrinkle Treatment -- Bloomberg
DJ
2020Evolus Provides Update on United States International Trade Commission (ITC) ..
GL
2020EVOLUS, INC. : Regulation FD Disclosure, Financial Statements and Exhibits (form..
AQ
2020DEADLINE REMINDER : Law Offices of Howard G. Smith Reminds Investors of Looming ..
PR
2020EOLS INVESTOR ALERT : Bronstein, Gewirtz & Grossman, LLC Reminds Evolus, Inc. Sh..
BU
2020THE LAW OFFICES OF FRANK R. CRUZ : Reminds Investors of Looming Deadline in the ..
BU
2020DEADLINE ALERT : Bragar Eagel & Squire, P.C. Reminds Investors That a Class Acti..
BU
2020EVOLUS : ROSEN, GLOBAL INVESTOR COUNSEL, Reminds Evolus, Inc. Investors of Impor..
BU
More news
Financials (USD)
Sales 2020 58,0 M - -
Net income 2020 -65,9 M - -
Net Debt 2020 - - -
P/E ratio 2020 -2,99x
Yield 2020 -
Capitalization 197 M 197 M -
Capi. / Sales 2020 3,39x
Capi. / Sales 2021 2,23x
Nbr of Employees 125
Free-Float 66,0%
Chart EVOLUS, INC.
Duration : Period :
Evolus, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends EVOLUS, INC.
Short TermMid-TermLong Term
TrendsBullishBullishNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 8
Average target price 7,13 $
Last Close Price 5,83 $
Spread / Highest target 88,7%
Spread / Average Target 22,2%
Spread / Lowest Target -31,4%
EPS Revisions
Managers and Directors
NameTitle
David Moatazedi President, Chief Executive Officer & Director
Vikram Malik Chairman
Alejandro Sabad Vice President-Operations
Lauren P. Silvernail Chief Financial & Accounting Officer
Rui Avelar Chief Medical Officer, Head-Research & Development
Sector and Competitors
1st jan.Capitalization (M$)
EVOLUS, INC.73.51%197
GILEAD SCIENCES, INC.8.70%79 386
VERTEX PHARMACEUTICALS-4.57%58 652
REGENERON PHARMACEUTICALS7.21%54 665
WUXI APPTEC CO., LTD.3.52%52 469
BEIGENE, LTD.33.52%31 458